Precision Targeting in Colorectal Cancer
Advancing BT-1501, an investigational oral therapy designed to target a core genetic driver of colorectal cancer.
APC Mutation: A Foundational Driver of Colorectal Cancer
The Adenomatous Polyposis Coli (APC) gene is a tumor suppressor responsible for regulating normal colon cell growth. Loss of APC function is observed in the majority of colorectal cancers and represents an early and foundational genetic event in disease progression.
Loss of functional APC disrupts cellular regulation and initiates a cascade of downstream genetic changes, including alterations in KRAS, TP53, SMAD4, and PIK3CA. These mutations contribute to tumor growth, progression, and metastasis.
Because APC mutation occurs early and is present in the majority of CRC tumors, it represents a broad and strategic biological target.
Targeting Synthetic Lethality in APC-Mutant Tumors
A precision-based strategy designed to selectively target cancer cells dependent on APC pathway dysfunction.
BT-1501 is designed to inhibit Emopamil Binding Protein (EBP), a molecular target identified as a vulnerability in APC-mutant colorectal cancer cells.
APC-mutant tumor cells rely on altered cellular stress and sterol-processing pathways for survival. By inhibiting EBP, BT-1501 is intended to disrupt this dependency, increasing cellular stress and triggering apoptosis (programmed cell death).
This approach is based on the principle of synthetic lethality — selectively targeting a weakness created by an existing genetic mutation.
An Oral, Once-Daily Investigational Therapy
Precision science, built around the needs of patients.
Unlike many colorectal cancer therapies that require intravenous administration, BT-1501 is being developed as a once-daily oral therapy.
Oral delivery may offer advantages in convenience, treatment flexibility, and potential combination strategies in future clinical development.
BT-1501 is designed to act at the molecular origin of tumor growth while maintaining the practicality of oral administration.
Preclinical Validation in Advanced CRC Models
Demonstrated tumor growth inhibition in human-relevant genetic models.
In human-relevant genetic mouse models of APC-mutant colorectal cancer, TASIN compounds, including BT-1501, demonstrated significant tumor growth inhibition.
• 63–74% tumor growth inhibition in advanced CRC animal models
• 40–60% reduction in tumor growth in CPC;Apc genetic mouse models
• Mechanistic validation of EBP inhibition pathway
These findings support further clinical development.
A Platform Approach to Targeted Oncology
BT-1501 represents the lead program within Barricade’s TASIN platform — a targeted strategy focused on exploiting mutation-driven vulnerabilities in cancer.
The company is advancing BT-1501 toward IND submission and Phase 1 clinical evaluation in advanced APC-mutant colorectal cancer.